Loading...

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Precision’s Abhishek Sharma Selected for World Heart Federation’s Emerging Leaders Program

2017-05-19T17:36:12-04:00News|

 

Congratulations to Associate Health Economist Abhishek Sharma, part of Precision’s Evidence Strategy, Generation, and Communications team, for his acceptance into the World Heart Federation’s Emerging Leaders (EL) program. The program is part of a WHF initiative to reduce premature mortality from noncommunicable, chronic diseases by 25% by 2025. (more…)

Precision’s Font at Asembia Summit: The Real Payers Are Employers

2017-05-08T20:05:40-04:00News|

At the Asembia Specialty Pharmacy Summit 2017, Precision for Value’s Jorge Font spoke about his presentation with Marie Rosenthal from Specialty Pharmacy Continuum on the significant impact big employers are having in revising the approaches to specialty pharmacy benefit administration and pricing. Font shared his perspective that the real payers are, in fact, employers.

(more…)

PHE’s ESGC Provides Critical Support to New Legislation, FDA Guidelines

2017-05-01T17:37:06-04:00News|

 

Congratulations to Precision Health Economics, and in particular the Evidence Strategy, Generation, and Communication (ESGC) practice group, for their outstanding efforts in support of the development of new legislation and FDA guidelines allowing biopharmaceutical manufacturers to more proactively share clinical and economic information with population health decision-makers on emerging therapies.

(more…)

Precision for Medicine and Philips Team Up to Achieve FDA Approval of the First Digital Pathology Solution for US Diagnostic Use

2017-04-20T20:51:49-04:00News|

 

Congratulations to the clinical trial and regulatory teams at Precision for Medicine: The FDA has just announced that the Philips PIPS (Philips IntelliSite Pathology Solution) has been approved through the de novo premarket review pathway as the first digital pathology solution for primary diagnostic use in the US.

This regulatory clearance signals a significant leap forward for the pathology services industry, and is expected to greatly boost adoption of digital pathology and collaboration.

Precision provided instrumental support to Philips in achieving this approval, monitoring the pivotal trial and working directly on the FDA strategy, including the successful effort to down-classify the system from a PMA Class III device to a Class II device (representing devices of a new type with low-to-moderate risk). This down-classification not only shortened the review time, but also reduces the regulatory burden going forward and streamlines the process for bringing incremental innovations to the US market.

For more information, click the link below to view the FDA press release.

Precision for Medicine and Precision Oncology CDM/EDC Teams Win Oracle Award

2017-04-13T18:27:26-04:00News|

 

Congratulations to our CDM and EDC teams from Precision Oncology and Precision for Medicine for being recognized by Oracle with the Excellence in Industry Service–Americas Award for 2017! Oracle was pleased to recognize Precision as an industry-leading, niche CRO dedicated to oncology studies and precision medicine initiatives. Another great example of the integration synergy generated on an ongoing basis—with Precision Oncology providing Oracle with clinical data management and Precision for Medicine providing electronic data capture builds.

Load More Posts